Evidence map›Paper›PMID 38162463›Full record

ArticleJournal of kidney cancer and VHL2023

Papillary Renal Cell Carcinoma: Demographics, Survival Analysis, Racial Disparities, and Genomic Landscape.

Asad Ullah, Abdul Qahar Khan Yasinzai, Naema Daino, Bisma Tareen, Zulfiqar Haider Jogezai, Haleema Sadia, Nimra Jamil, Girahnaz Baloch, Adil Karim, Kaleemullah Badini and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of kidney cancer and VHL, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Asad UllahDepartment of Pathology and Laboratory Medicine, Texas Tech University Health Sciences Center, Lubbock , TX, USA.
Abdul Qahar Khan YasinzaiDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Naema DainoMedical College of Georgia, Augusta, GA, USA.
Bisma TareenDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Zulfiqar Haider JogezaiAga University Medical College Pakistan.
Haleema SadiaKhyber Medical College, Pakistan.
Nimra JamilDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Girahnaz BalochDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Adil KarimDepartment of Internal Medicine, Integris Baptist Health, Oklahoma City, OK, USA.
Kaleemullah BadiniDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Agha WaliDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Abdul WaheedDepartment of Surgery, San Joaquin General Hospital, French Camp, CA, USA.
Marjan KhanDepartment of Internal Medicine, Marshfield Clinic, Marshfield, WI, USA.
Bina AsifBannu Medical College, Bannu, Pakistan.
Kaleemullah KakarDepartment of Medicine, Bolan Medical College, Quetta, Pakistan.
Saleh HeneidiDepartment of Pathology, Kaiser Permanente South Bay, Los Angeles, CA, USA.
Feroze SidhwaDepartment of Surgery, San Joaquin General Hospital, French Camp, CA, USA.
Nabin R KarkiDepartment of Hematology and Medical Oncology, University of South Alabama, Mobile, AL, USA.
Bolan Medical College · PKSan Joaquin General Hospital · USAugusta University · USKhyber Medical College · PKMarshfield Clinic · USUniversity of Science and Technology Bannu · PKUniversity of South Alabama Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary renal cell carcinoma (PRCC) is the second most common histological subtype of renal cell cancer. This research aims to present a large database study highlighting the demographic, clinical, and pathological factors, racial disparities, prognosis, and survival of PRCC. The clinical and demographic data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database, and molecular data was cured from the Catalogue Of Somatic Mutations in Cancer (COSMIC) database. PRCC had a median age of diagnosis at 64 years, with a higher incidence in men (77%), and Whites (68%). 70.3% of cases were Grades I-IV (13, 53, 31, and 3%, respectively). In patients with known data, 85% were localized to the kidney, and 84% of cases were 7 cm in size. No metastasis occurred in 97% of the known data. The most common treatment offered was surgical resection (9%). The 5-year overall survival was 79%, with patients undergoing surgery having a 90.6% 5-year survival. Multivariable analysis revealed age > 60 years, Black race, poor histologic differentiation, distant metastases, and tumor size > 10 cm as independent risk factors for mortality. The most common mutations identified from the COSMIC database were MET, KMT2D, KMT2C, ARID1A, and SPEN. PRCC affects male individuals in the sixth decade of life. Increased age, Black race, distant metastases, and tumors > 10 cm are associated with a worse prognosis. Surgical resection offers a favorable survival outcome. Next-generation sequencing (NGS) could identify potentially targetable alterations and future personalized therapeutic approaches.

Indexed as

COSMICnext-generation sequencingpapillary renal cell carcinomaSEER

Identifiers

PMID38162463
PMCPMC10755762
OpenAlexW4390439802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.